EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%
Göster/ Aç
Tarih
2020Yazar
Sezer, A.
Kilickap, S.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvilli, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Gladkov, O.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Gullo, G.
Lowy, I.
Rietschel, P.